Hidden Microplastic Threats Inside Our Bodies

Microplastics invade human blood, lungs, placenta, and even heart plaques, silently fueling inflammation and chronic diseases while functional medicine offers practical detox paths forward.

Story Snapshot

Humans ingest a credit card’s worth of microplastics weekly through food, air, water, and skin.
Detections in blood (2022), lungs, placenta, and atheromas (2024 NEJM) link particles to cardiovascular risks.
Functional medicine shifts from alarm to action with biomarker testing and gut-liver support protocols.
Short-term effects include oxidative stress; long-term threats involve CVD, cancer, and endocrine disorders.

Microplastics Enter Human Bodies Everywhere

Particles smaller than 5mm surged from 1950s plastic booms, detected environmentally since the 2000s. A 2019 Australian study calculated weekly human intake equivalent to a credit card via food packaging, bottled water, air, personal care products, and skin absorption. Liver processes these invaders, gut translocates them, triggering endocrine disruption. Pregnant women face placental crossover, exposing fetuses early. Clinics like Functional GYN document this invisible load in rising chronic cases.

Scientific Discoveries Confirm Internal Spread

2022 studies identified microplastics in human blood and lungs. Placentas tested positive post-2023, raising fetal harm alarms. The 2024 NEJM study found them in atheromas, predicting cardiovascular events. Toxicology research highlights inflammation and oxidative stress from gut microbe interactions (2023 Fardami studies). No direct causation proven yet, but biological plausibility demands response. Functional experts like Mark Hyman call this the missing chronic disease link.

Functional Medicine Leaders Develop Protocols

Mark Hyman, MD, hosts podcasts urging root-cause assessment over symptoms. Dr. Joseph Pizzorno advances detox strategies. Institute for Functional Medicine (IFM) practitioners from Richmond Functional Medicine, Toronto Functional Medicine Centre, Dr. Noble, and Haas Wellness Centers collaborate. They test biomarkers like 8-OHdG for oxidative stress, hs-CRP for inflammation, zonulin for gut permeability, and LPS. Huberman Lab episodes detail exposure cuts and excretion boosts. These leaders bridge NEJM rigor to clinic reality.

Three-Stage Clinical Frameworks Emerge

2023-2026 protocols follow assess-mitigate-restore phases. Stage one screens liver, gut, inflammation markers without direct particle tests, unproven today. Stage two deploys liver antioxidants, L-glutamine, probiotics, and fiber to bind and expel. Stage three builds resilience against sublethal effects. Therapeutic apheresis and microbial biodegradation show promise experimentally. Blogs and podcasts from 2025-2026 integrate these, rejecting wait-and-see approaches amid compelling evidence.

Health and Economic Ripples Unfold

Short-term, microplastics spark oxidative stress, hormonal chaos, liver strain. Long-term, they threaten CVD, cancer, autoimmunity, PCOS via mitochondrial and gut damage. All face exposure; pregnant women, CVD patients, chronic sufferers hit hardest. Functional medicine markets grow with detox supplements, fiber, probiotics demand. Clinics charge for panels, easing chronic burdens if scaled. Toxicology-clinical bridges spur environmental medicine innovation.